Association of fibrotic markers with diastolic function after STEMI
Publication date
2024-08-18
Authors
Al Ali, Lawien
Meijers, Wouter C.
Beldhuis, Iris E.
Groot, Hilde E.
Lipsic, Erik
van Veldhuisen, Dirk J.
Voors, Adriaan A.
van der Horst, Iwan C.C.
de Boer, Rudolf A.
van der Harst, Pim
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
cc_by_nc_nd
Abstract
Galectin-3 and Suppression of tumorigenicity-2 (ST2) are known markers of cardiac fibrosis. We investigated the prognostic value of fibrotic markers for the development of diastolic dysfunction and long-term outcome in patients suffering an ST-elevated myocardial infarction (STEMI). We analyzed 236 patients from the GIPS-III cohort with available echocardiographic studies and plasma measurements at hospitalization and after 4 months follow-up. Adjusted logistic mixed effects modelling revealed no association between the occurrence of diastolic dysfunction over time with abnormal plasma levels of galectin-3 and ST2. We observed no differences regarding survival outcome at follow-up of 5 years between patients with normal versus abnormal values in both galectin-3 (P = 0.75), and ST2 (P = 0.85). In conclusion, galectin-3 and sST2 were not associated with the development of diastolic dysfunction in non-diabetic patients that presented with a STEMI.
Keywords
General
Citation
Al Ali, L, Meijers, W C, Beldhuis, I E, Groot, H E, Lipsic, E, van Veldhuisen, D J, Voors, A A, van der Horst, I C C, de Boer, R A & van der Harst, P 2024, 'Association of fibrotic markers with diastolic function after STEMI', Scientific Reports, vol. 14, no. 1, 19122. https://doi.org/10.1038/s41598-024-69926-y